Patents Represented by Attorney, Agent or Law Firm F. Aaron Dubberley
-
Patent number: 6368826Abstract: The invention comprises a nucleic acid molecule with the sequence SEQ ID NO:5 and the complementary sequence, and its use in diagnosis and therapy. This nucleic acid molecule (IIP-10) is a gene which encodes an IGF-1 receptor binding polypeptide.Type: GrantFiled: December 2, 1999Date of Patent: April 9, 2002Assignee: Hoffmann-La Roche Inc.Inventors: Tanja Ligensa, Ralf Schumacher, Michael Weidner
-
Patent number: 6369222Abstract: The invention relates to nitro- and cyano-1,2,4,5-tetrahydro-heterocycloazepinyl pyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to medicaments containing such compounds and a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control or prevention of acute and/or chronic neurological disorders.Type: GrantFiled: July 11, 2001Date of Patent: April 9, 2002Assignee: Hoffmann-La Roche Inc.Inventors: Alfred Binggeli, Hans-Peter Maerki, Vincent Mutel, Wolfgang Wostl
-
Patent number: 6353111Abstract: 2,3-Di-substituted trans olefinic N-heteroaromatic or urido propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.Type: GrantFiled: December 1, 2000Date of Patent: March 5, 2002Assignee: Hoffmann-La Roche Inc.Inventors: Wendy Lea Corbett, Ramakanth Sarabu, Achyutharao Sidduri
-
Patent number: 6340742Abstract: Erythropoietin glycoprotein products are disclosed which have the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells. The present conjugates have an increased circulating half-life and plasma residence time, decreased clearance, and increased clinical activity in vivo. In addition, compared with conventional PEG-EPO conjugates, the conjugates of this invention have superior clinical properties. The present invention also includes a method for the treatment of anemia in a human employing the novel erythropoietin glycoprotein products as well as a method for preparing the erythropoietin glycoprotein products.Type: GrantFiled: June 28, 2000Date of Patent: January 22, 2002Assignee: Roche Diagnostics GmbHInventors: Josef Burg, Bernd Hilger, Hans-Peter Josel
-
Patent number: 6338950Abstract: The invention concerns a new immunoregulatory protein LST-1, nucleic acd sequences coding for this protein, a process for the isolation of this protein, as well as its use for the production of a therapeutic agent. The DNA and protein sequences are shown in SEQ ID NO:1 to 4.Type: GrantFiled: December 18, 1997Date of Patent: January 15, 2002Assignee: Roche Diagnostics GmbHInventor: Elisabeth Weiss
-
Patent number: 6331640Abstract: A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.Type: GrantFiled: September 29, 1999Date of Patent: December 18, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Nader Fotouhi, Paul Gillespie, Robert William Guthrie, Sherrie Lynn Pietranico-Cole, Weiya Yun
-
Patent number: 6326378Abstract: The present invention relates to the method of treating leukemia, lymphoma or inhibiting the proliferation of cells with a compound of formula I.Type: GrantFiled: October 5, 2000Date of Patent: December 4, 2001Assignee: Roche Diagnostics GmbHInventors: Walter-Gunar Friebe, Wolfgang Schaumann, Otto-Henning Wilhelms
-
Patent number: 6326156Abstract: The present invention relates to a method of screening for a therapeutically useful compound which comprises testing an LC132 receptor agonist in a screening assay for psychiatric and/or neurological disorders. More particularly, the screening method is based on contacting an LC132 receptor with an agent suspected of being an agonist of the LC132 receptor function, followed by the detection of the binding and/or the agonist activity of the compound and then testing of an agent with LC132 agonist activity in an antiepileptic, anticonvulsant or anxiolytic screening assay.Type: GrantFiled: June 3, 1997Date of Patent: December 4, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Olivier Civelli, James Richard Martin, Frederick Monsma, Jean-Luc Moreau, Hans-Peter Nothacker, Rainer Reinscheid
-
Patent number: 6320050Abstract: 2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.Type: GrantFiled: March 15, 2000Date of Patent: November 20, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Fred Thomas Bizzarro, Wendy Lea Corbett, Joseph Francis Grippo, Nancy-Ellen Haynes, George William Holland, Robert Francis Kester, Ramakanth Sarabu
-
Patent number: 6316593Abstract: This invention relates to a novel process for the synthesis of vasoactive intestinal peptide analog Ac(1-31)-NH2 from four protected peptide fragments.Type: GrantFiled: December 18, 1998Date of Patent: November 13, 2001Assignee: Hoffmann-La Roche Inc.Inventors: David Robert Bolin, Waleed Danho, Arthur M. Felix
-
Patent number: 6291685Abstract: The present invention is concerned with a novel process for the preparation of the hydroxybenzothiophene of formula I comprising cyclocarbonylation of a compound of formula II wherein Y is as defined in the specification, followed by saponification. The compound of Formula I is a building block of pharmaceutically active substances, e.g. 5-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenylmethyl]-2,4-thiazolidinedione and the corresponding sodium salt which are from agents useful in the treatment of diabetes.Type: GrantFiled: July 26, 2000Date of Patent: September 18, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Junghans, Michelangelo Scalone, Thomas Albert Zeibig
-
Patent number: 6258596Abstract: The present invention relates to variants of the human apolipoproteine A-I comprising a cystein in position 151, the corresponding nucleic acids and the vectors containing them. It also relates to pharmaceutical compositions comprising said elements and their utilization, particularly in genic therapy.Type: GrantFiled: June 5, 1998Date of Patent: July 10, 2001Assignee: Aventis Pharmaceuticals Products Inc.Inventors: Patrick Benoit, Eric Bruckert, Patrice Denefle, Nicolas Duverger, Jean-Charles Fruchart, Gérald Luc, Gérard Turpin, Gerd Assmann, Harald Funke
-
Patent number: 6248588Abstract: The present invention relates to a medium allowing the preservation and cryopreservation of biological materials such as animal cells and viral particles that are directly injectable or reinjectable into an organism. A medium for preserving and/or freezing biological materials, including a saline solution, modified fluid gelatin and human serum albumin, is disclosed.Type: GrantFiled: December 14, 1998Date of Patent: June 19, 2001Assignee: Aventis Pharms S.A.Inventors: André Crespo, Henri Michel Soria
-
Patent number: 6239296Abstract: Intermediate compounds useful for making phenylthiobutyl-isoquinoline compounds of formulaType: GrantFiled: February 25, 2000Date of Patent: May 29, 2001Assignee: Hoffmann-La Roche Inc.Inventor: Hans Hilpert
-
Patent number: 6239151Abstract: The invention provides hydrazine derivatives of the formula wherein R1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R2 is an acyl group derived from an &agr;-, &bgr;-, &ggr;- or &dgr;-(amino, hydroxy or thiol)carboxylic acid in which the amino, hydroxy or thiol group is optionally lower alkylated or the amino group is optionally acylated, sulphonylated or amidated and in which any functional group present in a side-chain is optionally protected, or a group of the formula Het(CH2)mCO; R3 is hydrogen, lower alkyl, halo-lower alkyl, cyano-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, heterocyclyl-lower alkyl, heterocyclylcarbonyl-lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl-lower alkenyl, aryl or heterocyclyl; R4 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a groupinType: GrantFiled: June 14, 1999Date of Patent: May 29, 2001Assignee: Hoffmann-La Roche Inc.Inventors: Michael John Broadhurst, William Henry Johnson, Daryl Simon Walter